A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma

New England Journal of Medicine

Volumn 335, Issue 2, 1996, Pages 91-97

  Attal, Michel ^a   Harousseau, Jean Luc ^b   Stoppa, Anne Marie ^c   Sotto, Jean Jacques ^d   Fuzibet, Jean Gabriel ^e   Rossi, Jean François ^f   Casassus, Philippe ^g   Maisonneuve, Hervé ^h   Facon, Thierry ⁱ   Ifrah, Norbert ^j   Payen, Catherine ^a   Bataille, Régis ^b  

^a CHU PURPAN   (France)

^b HÔTEL DIEU   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d HÔPITAL MICHALLON   (France)

^e University of Côte d'Azur   (France)

^f LAPEYRONIE HOSPITAL   (France)

^g AVICENNE HOSPITAL   (France)

^h CHD de la Roche sur Yon   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ D'ANGERS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 8944220233     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199607113350204     Document Type: Article

References (42)

1. Sporn JR, McIntyre OR. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 1986;13:318-5.
2. Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol 1989;25:159-61.
3. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822-4.
4. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62.
5. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869-72.
6. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298-301.
7. Barlogie B, Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1991;7:71-9.
8. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879-82.
9. Jagannath S, Barlogie B, Dicke K, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990;76:1860-6.
10. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-6.
11. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992;79:2827-33.
12. Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 1992; 10:47-51.
13. Anderson KC, Barut BA, Ritz J, et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991;77:712-20.
14. Reece DE, Barnett MJ, Connors JM, et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993;11:139-46.
15. Fermand JP, Chevret S, Ravaud P, et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993;82:2005-9.
16. Reiffers J, Marit G, Boiron JM. Autologous blood stem cell transplantation in high-risk multiple myeloma. Br J Haematol 1989;72:296-7.
17. Gianni AM, Tarella C, Bregni M, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994;12:503-9.
18. Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994;12:764-8.
19. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
20. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84:950-6.
21. Björkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995;15:367-71.
22. Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;82:2324-8.
23. Bjorkstrand B, Ljungman P, Bird JM, et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995;13:Suppl 2:140-6.
24. Alexanian R, Dimopoulous MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994;84:4278-82.
25. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077-85.
26. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
27. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
28. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA 1992;268:2946-51.
29. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
30. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322: 1430-4.
31. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995;31A:146-51.
32. Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1994;12:2405-14.
33. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-76.
34. α2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial. Blood 1995;86:Suppl 1:441a. abstract.
35. Westin J. Interferon-alfa-2b in addition to melphalan-prednisone for initial and maintenance treatment in multiple myeloma: a randomized Nordic trial. Blood 1995;86:Suppl 1:441 a. abstract.
36. Casassus P, Pegourie-Bandelier B, Sadoun A, et al. Randomized comparison of interferon-α with VMCP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicentre triai. Blood 1995;86:Suppl 1:441a. abstract.
37. Barlogie B, Crowley J, Jagannath S, et al. Superior outcome after early autotransplantation (AT) with "total therapy" (TT) compared to standard SWOG treatment (ST) for multiple myeloma (MM). Blood 1995;86:Suppl 1:207a. abstract.
38. Fermand JP, Ravaud P, Chevret S,et al. High dose therapy (HDT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with HDT rescue in multiple myeloma (MM): results of a prospective randomized trial. Blood 1995;86:Suppl 1:205a. abstract.
39. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy: for multiple myeloma. Lancet 1989;2:882-5.
40. Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992;80:2188-95.
41. Gisselbrecht C, Prentice HG, Bacigalupo B, et al. Placebo-controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994;343:696-700.
42. Harousseau JL, Attal M, Divine M, et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995;15:963-9.